Novo Nordisk Buys Akero: Betting Big on Liver Disease
A $5.2B deal adds a Phase 3 MASH candidate and broadens Novo’s cardiometabolic platform beyond GLP‑1s.
Novo Nordisk’s agreement to acquire Akero Therapeutics for up to $5.2 billion is more than bo...